Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to find a sustainable balance between government and industry to ensure patients receive world-class healthcare. Furthermore, they highlight the importance of the biosimilar boom for European healthcare budgets and the importance of the Polish market for Mylan.
What does it mean to be an independent global generics company within Europe in 2018?
"Looking ahead, Mylan observes an outstanding opportunity in the field of biosimilars, and this area is set to develop massively."
